li001

The Phase 3 PSMAddition study tested whether adding lutetium Lu 177 vipivotide tetraxetan (Pluvicto) to standard treatment improves outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Patients received either standard therapy with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI), or the same treatment plus up to six cycles of Pluvicto.

Treatment with selinexor (Xpovio) for relapsed or refractory multiple myeloma is moving toward lower, more tolerable dosing. “Less is often more,” focusing on keeping patients on therapy longer rather than using high doses that cause more side effects. Instead of the older high-dose schedule of 80 mg twice weekly, doctors now favor a lower weekly

Final results show that combining radium-223 (Xofigo) with enzalutamide (Xtandi) helps patients with bone-predominant metastatic castration-resistant prostate cancer live longer than treatment with enzalutamide alone. Patients who received the combination lived a median of 38.2 months, compared with 32.6 months for those on enzalutamide alone. The combination also delayed visible tumor growth on scans, extending

New data from the Phase 2 BRCAAway trial presented at the 2026 Genitourinary Cancers Symposium show that combining abiraterone, prednisone, and olaparib provides major benefits for patients with metastatic castration-resistant prostate cancer who carry BRCA1/2 or ATM mutations. The three-drug combination significantly outperformed either abiraterone or olaparib alone. Patients receiving the combination had a progression-free

Researchers have found a new way to help immunotherapy work better for patients with aggressive, recurrent high-grade astrocytoma, a serious type of brain cancer. One of the biggest challenges in treating brain tumors is the blood-brain barrier. This natural protective barrier prevents many drugs and immune cells from entering the brain, including treatments designed to